Výsledky vyhledávání - "HER2 Antibody"

Akademický článek

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer

Autor: Jangsoon Lee, Kumiko Kida, Jiwon Koh, Huey Liu, Ganiraju C. Manyam, Young Jin Gi, Dileep R. Rampa, Asha S. Multani, Jing Wang, Gitanjali Jayachandran, Dae-Won Lee, James M. Reuben, Aysegul Sahin, Lei Huo, Debu Tripathy, Seock-Ah Im, Naoto T. Ueno

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-20 (2024)

Abstract Background Anti-HER2 therapies, including the HER2 antibody–drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have led to improved survival outcomes in patients with HER2-overexpressing (HER2+) metast

Externí odkaz: https://doaj.org/article/96dec9fe852b4c2f9909c30d5560016b

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparison of Dako HercepTest and Ventana PATHWAY anti-HER2 (4B5) tests and their correlation with silver in situ hybridization in lung adenocarcinoma

Autor: Ljiljana Vuckovic, Mirjana Miladinović, Aleksandra Klisic

Publikováno v: Open Medicine, Vol 16, Iss 1, Pp 1503-1512 (2021)

Background Discordant results exist about the role of human epidermal growth factor receptor 2 (HER2) overexpression and/or HER2 amplification in lung adenocarcinoma. We aimed to compare the performance of HercepTest and PATHWAY anti-HER2 (4B5) by co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab4e1c22fdd62ecdc30eb2556eb213e8
https://doaj.org/article/5f7c00daba9c4f91a24722282c2aff61

Zobrazit plný text záznamu

Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody–Drug Conjugates

Autor: Ludovic Juen, Camille Gély, Audrey Desgranges, Ofelia Feuillâtre, Nicolas Joubert, Camille Martin, Christine B. Baltus, Marie-Claude Viaud-Massuard, Steve Huvelle

Publikováno v: ACS Omega
ACS Omega, Vol 5, Iss 3, Pp 1557-1565 (2020)

Antibody–drug conjugates (ADCs) are the spearhead of targeted therapies. According to the technology used, the conjugation of a cytotoxic drug to an antibody can produce suboptimal heterogeneous species, impacting the overall efficacy. Herein, we d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eca9a84065672450d88c66b3dac2ce2
https://doi.org/10.1021/acsomega.9b03510

Zobrazit plný text záznamu

A study of HER2 expression in endometrial carcinoma: a single centre experience

Autor: Azmawati Mohammed Nawi, Hasmah Hashim, Nurwardah Alfian, Suria Hayati Md Pauzi, Mariani Hashim, Nur Maya Sabrina Tizen

Publikováno v: Pan African Medical Journal; Vol. 38 No. 1 (2021)
The Pan African Medical Journal

Introduction:endometrial carcinoma (EC) is the seventh most common cancer in females in Malaysia, of which the majority is composed of lower grade type I EC. Although less prevalent, type II EC which is of higher grade has poorer outcome and prognosi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a67eaa5884cef09dea9fc54a6dc52d5
https://www.ajol.info/index.php/pamj/article/view/237391

Zobrazit plný text záznamu

Reagent-saving immunohistochemistry for HER2 using non-contact alternating current electric field mixing

Autor: Yoichi Akagami, Kaori Terata, Ryuta Nakamura, Satoru Motoyama, Yoshitaro Saito, Hajime Saito, Satoshi Fujishima, Kazuhiro Imai, Hiroshi Nanjo, Yoshihiro Minamiya, Akiyuki Wakita, Iku Hoshino, Yusuke Sato

Publikováno v: Journal of Clinical Pathology. 72:25-30

AimsHuman epidermal growth factor receptor 2 (HER2)-targeted agents are an effective approach to treating patients with HER2-positive breast cancer. However, the lack of survival benefit in HER2-negative patients, as well as the toxic effects and hig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8640b64f80378d0e8da0f2c41969505b
https://doi.org/10.1136/jclinpath-2018-205325

Zobrazit plný text záznamu

Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1

Autor: Matthew Sung, Edmund I. Graziani, Paul Jasper, John E. Tolsma, Frank Barletta, Dangshe Ma, Piet H. van der Graaf, Edward Rosfjord, Tracey Clark, Alison Betts

Publikováno v: Journal of Pharmacokinetics and Pharmacodynamics

A modeling and simulation approach was used for quantitative comparison of a new generation HER2 antibody drug conjugate (ADC, PF-06804103) with trastuzumab-DM1 (T-DM1). To compare preclinical efficacy, the pharmacokinetic (PK)/pharmacodynamic (PD) r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb671c4e8e42cc2410ccef7e753f3e38
https://pubmed.ncbi.nlm.nih.gov/32710210

Zobrazit plný text záznamu

Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer

Autor: Meiting Chen, Su Li, Herui Yao, Cong Xue, Yugang Dong, Xin An, Yanxia Shi, Ying Lin

Publikováno v: Journal of Clinical Oncology. 39:1042-1042

1042 Background: LZM005 is a novel anti-HER2 antibody that binds with elevated affinity to the domain II of HER2. This phase I study assessed the safety, tolerability, pharmacokinetics (PK) and activity of LZM005, as monotherapy or combined with tras

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1a5efe9f7e04b57318107a133b173ead
https://doi.org/10.1200/jco.2021.39.15_suppl.1042

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání